The lack of an effective drug therapy against ossification of spinal ligament (OSL) warrants investigation into the therapeutic target of this disease. An endogenous inhibitor of biomineralization, pyrophosphate (PPi) is a potential therapy for ectopic ossification; however, exogenous PPi is rapidly hydrolyzed by tissue non-specific alkaline phosphatase (TNAP) present in body fluids. In this study, we examined whether a drug therapy targeting PPi is efficacious for the treatment of OSL using the Enpp1 ttw/ttw (twy) mouse model. Twenty male twy mice were randomized into four groups: (i) vehicle (Control); (ii) alkaline phosphatase inhibitor levamisole (5 mg/kg/day sc continuously); (iii) levamisole þ exogenous PPi (160 mmol/kg/day sc continuously); and (iv) nuclear retinoic acid receptor-g (RARg) agonist (6 mg/kg sc daily). The RARg agonist, which is a proven inhibitor of ectopic endochondral ossification, was used as a positive control. Treatments commenced when the mice were 5 weeks of age and continued for 4 weeks. Longitudinal micro-computed tomography and postmortem histological analysis were performed. Administration of levamisole alone and in combination with PPi increased serum PPi concentration by 17% and 52%, respectively, compared to that in vehicle-treated mice. The development of OSL in twy mice was suppressed by levamisole þ PPi and RARg agonist treatments, but not by levamisole alone. The levamisole þ PPi therapy did not cause osteoporosis, whereas RARg agonisttreated mice developed osteoporosis. Treatment of twy mice with levamisole in combination with exogenous PPi increased serum PPi level, which slowed the progression of OSL without producing adverse effect on bone. ß
Ossification of the spinal ligaments (OSL) is a common skeletal disorder of unknown etiology characterized by ectopic ossification of the spinal ligaments. [1] [2] [3] [4] Patients with diffuse idiopathic skeletal hyperostosis (DISH) suffer from immobilization of the spine. 5 Patients with ossification of posterior longitudinal ligaments of the spine (OPLL) develop various degrees of myelopathy as well as ankylosis of the spine.
Since no effective drug therapy is established for OSL, there is a need to identify the therapeutic target for this disease. Pyrophosphate (PPi), an endogenous inhibitor of biomineralization, is a potential therapy for ectopic ossification; however, exogenously administered PPi is rapidly hydrolyzed by tissue non-specific alkaline phosphatase (TNAP) that is ubiquitously present in body fluids. 6 A recent study showed that the half-life of PPi is 33 min and that only a transient increase in the plasma concentration of PPi was noted with exogenous PPi therapy. 7 To maintain tissue concentration of PPi, administration of the alkaline phosphatase inhibitor, levamisole may be useful. Levamisole is a drug used to treat parasitic worm infections in both humans and animals, but it was also shown to prevent bone mineralization by inhibiting alkaline phosphatase activity. 8 Therefore, levamisole could potentially increase tissue concentration of endogenous PPi by inhibiting TNAP, thus leading to inhibition of ectopic ossification. We also hypothesized that administration of exogenous PPi in combination with levamisole may increase and maintain tissue concentration of PPi.
One potential problem with the use of alkaline phosphatase inhibitors is their adverse effect on normal bone metabolism. In the genetic disorder of hypophosphatasia, inactive TNAP produced by mutated TNAP gene causes defective bone mineralization, resulting in skeletal abnormality. Therefore, it is necessary to determine whether levamisole affects systemic bone metabolism and leads to osteoporosis or osteomalacia.
In this study, we investigated the efficacy and safety of levamisole alone and in combination with exogenous PPi for the treatment of OSL using Enpp1 ttw/ttw tip-toe walking Yoshimura (twy) mouse model for OSL. Furthermore, we assessed the efficacy and safety of a nuclear retinoic acid receptor-g (RARg) agonist CD1530, which is a proven inhibitor of ectopic endochondral ossification, as a positive control.
MATERIALS AND METHODS

Mice
Twy mice are mutant mice showing multiple osteochondral lesions, and have been used as a model for DISH and OPLL. 5, 9 The twy mice used in this study are maintained by brother-sister mating of heterozygote ICR mice at the Central Institute for Experimental Animals (Kawasaki, Japan). Twy mice harbor an autosomal recessive mutation in the ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (Enpp1) gene. Systemic calcification and tip-toe walking of twy mice occur immediately after weaning and progress within a short period of time. From they eventually begin to die at 12 weeks of age, with the majority dying before 30 weeks of age. [10] [11] [12] [13] [14] [15] [16] Twy mice develop ectopic ossification, which is defined as mineralized bone matrix containing osteoblasts and osteocytes, in the anterior spinal longitudinal ligament, and also develop ectopic calcification, which is defined as mineralized matrix without living cells, in the posterior atlantoaxial membrane. 5 Twy mice were housed in groups under a 12-h light/dark cycle with ad libitum access to food and water. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Hokkaido University.
Study Design
Twenty male twy mice were randomized into four groups: (i) vehicle (Control); (ii) levamisole; (iii) levamisole þ PPi; and (iv) RARg agonist (positive control). Saline or RARg agonist (Tocris Bioscience, Bristol, UK) were administered to the mice via subcutaneous injections daily from 5 weeks of age for 4 weeks. Levamisole hydrochloride (Nacalai Tesque Inc., Kyoto, Japan) in combination with or without sodium pyrophosphate decahydrate (Sigma Aldrich, St. Louis, MO) were diluted in propylene glycol and delivered subcutaneously from Alzet osmotic minipumps (Muromachi Kikai Co., Ltd., Tokyo, Japan). The mice received a subcutaneous implant of the minipumps at 5 weeks of age, and the pumps were replaced 2 weeks after the initial implantation. Levamisole and exogenous PPi were delivered using continuous infusion pumps because the half-life of PPi is only 33 min and transient increase in PPi level was considered insufficient to inhibit ectopic ossification.
Each dosage amount was determined based on previous reports 7, 17, 18 : levamisole, 5 mg/kg/day; PPi, 160 mmol/kg/day; and RARg agonist, 6 mg/kg/day. After 4 weeks, the mice were anesthetized with a 5 ml/g cocktail of ketamine (20 mg/ml) and xylazine (2 mg/ml) and sacrificed ( Fig. 1) . Longitudinal micro-computed tomography and postmortem histological analysis were performed.
Measurement of Serum PPi Level
Blood was collected at the time of sacrifice. Serum was separated from blood via centrifugation (30 min, 3,000 rpm) and stored in single-use aliquots at À80˚C until analysis. Serum PPi levels were measured using a fluorometric pyrophosphate assay kit (Abcam, Cambridge, UK) according to the manufacturer's protocol. Serum PPi levels in 9-weekold male ICR mice (background strain of twy mice) were also measured as reference data.
Micro-Computer Tomography (CT) Analysis
Cervical and lumbar spines were scanned individually using micro-CT (R_mCT2; Rigaku, Tokyo, Japan) at 10-mm isotropic resolution. Because the cervical vertebrae were too small to evaluate the trabecular structure, we measured structural parameters of the 5th lumbar vertebral body of the spine. Measurements were performed using TRI/3D-BON software (Ratoc System Engineering Co., Tokyo, Japan) in accordance with the guidelines described by Bouxsein et al. The centrum of each specimen, from the cephalad to caudal endplate and inside the endosteal margin, was analyzed to assess trabecular bone morphology. The following indices were calculated: Trabecular bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th), and trabecular number (Tb.N).
Ankylosis of the cervical spine was evaluated according to Mata's score, which grades DISH on a scale of 0-4 based on ossification at each disc space level, where 0 ¼ no ossification, 1 ¼ ossification without bridging, 2 ¼ ossification with incomplete bridging, 3 ¼ complete bridging of the disc space, and 4 ¼ severe ossification. 19 We scored the second until the seventh cervical vertebra at each disc space level, with a maximum score of 20.
In addition, quantitative analysis of the volume of ectopic calcification at the posterior atlantoaxial membrane was performed based on CT-DICOM data using the TRI/3D-BON software.
We performed repeated micro-CT observations of the same mice to get longitudinal data. Baseline data were obtained at 5 weeks of age under general anesthesia and then the second data were obtained at 9 weeks of age.
Histological Analysis
For dynamic bone formation analysis, calcein (20 mg/kg; Dojindo Laboratories, Kumamoto, Japan) was injected subcutaneously 5 days and 1 day before the mice were killed. The cervical spines were fixed in 70% ethanol and stained with Villanueva bone stain. The specimens were then subjected to undecalcified tissue processing. The specimens were embedded in methyl methacrylate (MMA; Wako Chemicals, Kanagawa, Japan) and sectioned at 5 mm in the sagittal plane. The cervical spine was examined by fluorescence microscopy to evaluate the dynamic parameters of bone formation. Histomorphometric analysis was performed using ImageJ software (NIH, Bethesda, MD). The measured parameters of trabecular bone of the 6th vertebral body included the percentage of osteoid volume (OV/BV), bone surface (BS), single-labeled surface (sLS), and double-labeled surface (dLS), mineral apposition rate (MAR), and bone formation rate (BFR) in accordance with the standard nomenclature proposed by Dempster et al.
Statistical Analysis
One-way analysis of variance with Tukey's multiple comparison test was performed to compare data in all groups. All data are expressed as means AE standard deviations (SD). A p value of less than 0.05 was considered statistically significant.
RESULTS
General Condition
During the treatment period, body size and weight increased in twy mice in the control group (from 5 to 9 weeks of age). Increase in body size and weight in the levamisole and levamisole þ PPi groups were 
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comparable to that in the control group. However, body weight and body weight gain of mice in the RARg agonist group was significantly lower than those of mice in the other groups after 4 weeks of treatment (Fig. 2) . Further, mice in the RARg group exhibited mild mucosal damage.
Serum Concentration of PPi
Serum concentration of PPi in twy mice was 15% lower than that in healthy ICR mice (background strain of twy mice), possibly because of the mutation in the Enpp1 gene (Fig. 3) . Serum concentration of PPi increased by an average of 17% in levamisole-treated twy mice, and by an average of 52% in twy mice treated with levamisole in combination with exogenous PPi, compared to that in vehicle-treated twy mice.
Effect of Levamisole, Levamisole þ PPi, and RARg Agonist on Ankylosis of the Spine and Ectopic Calcification in Twy Mice
To elucidate the effect of levamisole, levamisole þ PPi, and RARg agonist on the OSL, we longitudinally assessed the ankylosis of the spine in twy mice using micro-CT images taken under anesthesia and after the mice were sacrificed. Reconstructed micro-CT images showed that levamisole in combination with PPi, but not levamisole alone, suppressed the progression of ankylosis of the cervical spine (Fig. 4A) . Similarly, the RARg agonist also suppressed the progression of the ankylosis. The spinal ankylosis score (Mata's score) increased with time in all groups, but those in the levamisole þ PPi and RARg groups were significantly lower than that in the control group after 4 weeks of treatment (Fig. 4B) .
To better understand the mechanism responsible for the change induced by the above therapies, we histologically analyzed sagittal sections of the cervical spine specimens after 4 weeks of treatment (Fig. 5) . Unorganized cartilage and irregular calcification were seen around the protruded intervertebral discs of the mice; despite that, no pronounced inflammatory cell infiltration was noted. Moreover, osseous bridges were observed across the outer layer of the annulus fibrosus of the intervertebral discs and spinal ligaments. Fluorescence microscopy showed labeled bone surfaces in the osseous bridges, indicating that active bone formation was in progress in this region ( Fig. 5E and F). These histological features were similarly seen in the levamisole alone group, but fewer osseous bridge formations were observed between the enthesis regions of vertebral bodies in both levamisole þ PPi and RARg agonist groups ( Fig. 5G and H) .
Ectopic calcification at the posterior atlantoaxial membrane were sparsely observed in twy mice at 5 weeks of age, but its volume increased over time. Although both levamisole þ PPi and RARg agonist therapies tended to suppress ectopic calcification, the differences were not statistically significant (Fig. 4C) .
Effect of Levamisole, Levamisole þ PPi, and RARg Agonist on Physiological Bone Remodeling in Twy Mice
To evaluate any potential adverse effects of the different treatments on bone, we longitudinally assessed the bone volume and microstructure of the trabecular bone of the 5th lumbar vertebral body using micro-CT imaging ( Fig. 6A and B) . Levamisole, both alone and in combination with PPi, had no significant impact on bone volume, whereas the RARg agonist induced significant bone loss in mice between 5 and 9 weeks of age. In addition, the representative microstructural indices, Tb.Th, and Tb.N, were significantly smaller in the RARg agonist group than in the other three groups.
To identify the effect of these therapies on dynamic bone formation, we analyzed the undecalcified midsagittal sections of the cervical vertebrae (Fig. 6D) . MAR and BFR/BS in trabecular bone were significantly lower in the RARg agonist group than in the control group (Fig. 6C) . Levamisole þ PPi therapy showed only a tendency to decrease MAR and BFR/BS, but the value of OV/BV, which represents the percentage of unmineralized immature bone to total bone, was significantly greater in the levamisole þ PPi group than in the control group. 
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DISCUSSION
The first question addressed in this study is whether the alkaline phosphatase inhibitor, levamisole increases tissue concentration of endogenous PPi and inhibits OSL. Although administration of levamisole led to a 17% increase in serum concentration of PPi, it did not have a significant effect on the progression of OSL. Given that daily doses of 40 and 80 mg/kg/day levamisole were reported to inhibit bone mineralization in mice, higher doses of levamisole might exert inhibitory effect on the progression of OSL. 17 However, doses of 40 mg/kg/day resulted in marked body weight loss in our preliminary study. In contrast, a dose of 5 mg/kg/day levamisole appeared to be well tolerated and was therefore used to test our hypothesis. Moreover, a single dose of 2.5 mg/kg/day levamisole as recommended for use in humans by the World Health Organization further supports the administration of 5 mg/kg/day levamisole in this study.
The second question raised in this study is whether levamisole in combination with exogenous PPi increases tissue concentration of PPi and slows the progression of OSL. Although we could not measure the local tissue concentration of PPi due to technical difficulty, we observed a 52% increase in the serum concentration of PPi in mice treated with levamisole and PPi. Micro-CT analysis demonstrated that while levamisole in combination with PPi did not shrink the size of existing OSL, it successfully suppressed the expansion of OSL comparable to that induced by RARg agonist therapy, as supported by Mata's spinal ankylosis score and histological observations. This suggests that a 52% increase in PPi serum concentration is sufficient to inhibit ectopic ossification, but not the more modest increase of 17%. Given that serum concentration of PPi in twy mice was 15% lower than that in healthy ICR mice (background strain of twy mice), it is likely that supraphysiological level of PPi is necessary to suppress the progression of spinal ossification once it is formed.
The inhibitory effect of levamisole in combination with exogenous PPi on the progression of OSL is presumed to result from an increase in the tissue concentration of PPi in spinal ligaments, which in turn led to inhibition of hydroxyapatite crystal formation. Hence, administration of exogenous PPi alone may be 
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effective to control the progression of OSL. However, owing to the short half-life of PPi, exogenous PPi therapy could not maintain the activity when preserved in the osmotic minipump in our preliminary study (data not shown) and therefore be considered ineffectual in sufficiently maintaining the concentration of PPi to inhibit OSL. Therefore, concurrent administration of an alkaline phosphatase inhibitor with PPi is a rational combination therapy to prolong the half-life of exogenous PPi. Nevertheless, the optimal dosing strategy should be identified in future studies because continuous delivery of the mixture of levamisole and PPi may be the reason for the success of this therapy. Drug-induced osteoporosis is a major concern with regard to drug therapies against heterotopic ossification because they potentially have a negative impact on bone formation. Although 4 weeks of treatment with levamisole and PPi did not elicit any significant effect on bone volume as well as dynamic bone formation parameters, histomorphometric data showed an increase in the percentage of osteoid volume (unmineralized immature bone), suggesting that the therapy negatively impacted the mineralization of newly formed bones. Therefore, long-term use of levamisole and PPi might adversely affect systemic bone remodeling. The reason why the levamisole and PPi therapy preferentially acts on OSL remains unknown. Based on the finding that alkaline phosphatase is highly expressed in cells at the OSL lesion, 14 the therapy is more likely to affect heterotopic ossification in which TNAP is highly expressed.
As expected based on earlier studies demonstrating that RARg agonists effectively inhibited heterotopic ossification in injury-induced and genetic mouse models of fibrodysplasia ossificans progressiva, 18, 20, 21 the RARg agonist therapy used in this study inhibited the progression of OSL. However, it should be noted that the RARg agonist also significantly suppressed bone formation, resulting in deterioration of the microarchitecture of trabecular bone as well as decrease in bone volume. This observation can be explained based on the mechanism that liganded RARg interacts directly with 
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smad proteins and inhibits their function, which is important for the differentiation and function of both chondrocytes and osteoblasts. Therefore, administration of RARg agonists might lead to the development of osteoporosis, despite their therapeutic effect on OSL. This study has several limitations. First, the age of the mice was too young relative to the human age at the onset of OSL which is predominantly over 40 years. The reason we commenced treatment from the age of 5 weeks is because twy mice develop ossification and calcification at this age and sometimes die after the age of 12 weeks due to paraplegia, which is caused by spinal cord compression accompanied by the development of ossification or calcification of spinal ligaments. Second, although we selected the treatment dosage used in this study based on previous reports, there might be differences in dosage for humans and animals. Therefore, further studies to determine the optimal dose and dosing maneuver should be performed before any clinical application. Third, we studied the effect of drug therapy on ectopic ossification/ calcification focusing on the spinal ligaments in this study. However, the effects of drug therapy on ectopic ossification/calcification in other tissues such as tendon, muscle, and artery are of great interest because these soft tissues sometimes develop pathological mineralization. Therefore, the effect of drug therapy on other tissues should be examined in future study.
In conclusion, this study showed that the alkaline phosphatase inhibitor levamisole in combination with exogenous PPi increased serum PPi level in the twy mouse model of OSL, which slowed the progression of OSL without producing adverse effect on bone.
